Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial

BACKGROUND: Immune checkpoint blockade with monoclonal antibodies targeting programmed death 1 (PD-1) and its ligand PD-L1 has played a major role in the rise of cancer immune therapy. We have identified naturally occurring self-reactive T cells specific to PD-L1 in both healthy donors and cancer pa...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Immunol
Autors principals: Jørgensen, Nicolai Grønne, Klausen, Uffe, Grauslund, Jacob Handlos, Helleberg, Carsten, Aagaard, Thomas Granum, Do, Trung Hieu, Ahmad, Shamaila Munir, Olsen, Lars Rønn, Klausen, Tobias Wirenfeldt, Breinholt, Marie Fredslund, Hansen, Morten, Martinenaite, Evelina, Met, Özcan, Svane, Inge Marie, Knudsen, Lene Meldgaard, Andersen, Mads Hald
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2020
Matèries:
Immunology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7680803/
https://ncbi.nlm.nih.gov/pubmed/33240282
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.595035
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars